Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 16;12(10):2361.
doi: 10.3390/biomedicines12102361.

Peptide-Based Inhibitors of Protein-Protein Interactions (PPIs): A Case Study on the Interaction Between SARS-CoV-2 Spike Protein and Human Angiotensin-Converting Enzyme 2 (hACE2)

Affiliations
Review

Peptide-Based Inhibitors of Protein-Protein Interactions (PPIs): A Case Study on the Interaction Between SARS-CoV-2 Spike Protein and Human Angiotensin-Converting Enzyme 2 (hACE2)

Aizhan Rakhmetullina et al. Biomedicines. .

Abstract

Protein-protein interactions (PPIs) are fundamental to many critical biological processes and are crucial in mediating essential cellular functions across diverse organisms, including bacteria, parasites, and viruses. A notable example is the interaction between the SARS-CoV-2 spike (S) protein and the human angiotensin-converting enzyme 2 (hACE2), which initiates a series of events leading to viral replication. Interrupting this interaction offers a promising strategy for blocking or significantly reducing infection, highlighting its potential as a target for anti-SARS-CoV-2 therapies. This review focuses on the hACE2 and SARS-CoV-2 spike protein interaction, exemplifying the latest advancements in peptide-based strategies for developing PPI inhibitors. We discuss various approaches for creating peptide-based inhibitors that target this critical interaction, aiming to provide potential treatments for COVID-19.

Keywords: ACE2; COVID-19; SARS-CoV-2; angiotensin-converting enzyme 2; coronavirus; drug design; inhibitors of protein–protein interactions; peptides.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The complex structure of hACE2 and SARS-CoV-2 spike proteins (PDB id: 6m0j)— computer-generated, cartoon representation. (a) The interaction interface between hACE2 (blue) and the spike (orange) is shown as the solvent accessible surface area and highlighted by magenta and cyan colors, respectively; (b,c) depicted amino acid residues forming the interface for a particular protein are shown as sticks in this representation; (d) schematic diagram of interactions between proteins. Residues are colored according to the type: positive (H, K, R); negative (D, E); S, T, N, Q = neutral; A, V, L, I, M = aliphatic; F, Y, W = aromatic; G = Gly. Type of contacts: hydrogen bonds (blue line); salt bridges (red line); nonbonded contacts (gray dash line). Protein visualization was prepared by the PyMOL Molecular Graphics System, Version 3.0.0 Schrödinger, LLC.

Similar articles

Cited by

References

    1. Henninot A., Collins J.C., Nuss J.M. The Current State of Peptide Drug Discovery: Back to the Future? J. Med. Chem. 2018;61:1382–1414. doi: 10.1021/acs.jmedchem.7b00318. - DOI - PubMed
    1. Wang L., Wang N., Zhang W., Cheng X., Yan Z., Shao G., Wang X., Wang R., Fu C. Therapeutic Peptides: Current Applications and Future Directions. Signal Transduct. Target. Ther. 2022;7:48. doi: 10.1038/s41392-022-00904-4. - DOI - PMC - PubMed
    1. Lee A.C.-L., Harris J.L., Khanna K.K., Hong J.-H. A Comprehensive Review on Current Advances in Peptide Drug Development and Design. Int. J. Mol. Sci. 2019;20:2383. doi: 10.3390/ijms20102383. - DOI - PMC - PubMed
    1. Lau J.L., Dunn M.K. Therapeutic Peptides: Historical Perspectives, Current Development Trends, and Future Directions. Bioorganic Med. Chem. 2018;26:2700–2707. doi: 10.1016/j.bmc.2017.06.052. - DOI - PubMed
    1. Cabri W., Cantelmi P., Corbisiero D., Fantoni T., Ferrazzano L., Martelli G., Mattellone A., Tolomelli A. Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives. Front. Mol. Biosci. 2021;8:697586. doi: 10.3389/fmolb.2021.697586. - DOI - PMC - PubMed

LinkOut - more resources